IHE News

IHE to provide economic evaluation for $1.4 million provincial research project

The IHE partners with Metabolomic Technologies Inc., Alberta Innovates, Alberta Health Services, University of Alberta, and DynaLIFE Medical Labs, for the Canadian Assessment of PolypDx™ research project.

Colorectal cancer is the second most commonly diagnosed cancer in Canada, and is the second and third leading cause of cancer-related deaths for men and women, respectively. With early detection through screening, this form of cancer is preventable, yet half of all colorectal cancers in Canada are diagnosed at stage III or IV. The five-year survival rate decreases from 90% to less than 15% when colorectal cancer is diagnosed at stage I versus stage IV.1

This $1.4 million research project, supported by Alberta Innovates, will be assessing a new colorectal cancer screening strategy using Metabolomic Technologies Inc.’s PolypDx™, the first and only urine test for detecting colorectal polyps and cancer. The project will bring together the Alberta Colorectal Cancer Screening Program, Alberta Health Services Health Technology Assessment & Innovation, Alberta Health Services Public Laboratory Services, Digestive Health Strategic Clinical Network, University of Alberta, DynaLIFE Medical Labs, and the IHE, with the IHE performing an economic evaluation of the PolypDx™ screening test in comparison with current practice (fecal immunochemical test, or FIT).

The Canadian Assessment of PolypDx™ research project will engage with expert physicians, clinicians, patients, and laboratory specialists to address issues of compliance and accessibility through utility studies of 3,000 patients in five clinics throughout Alberta. A working group of key provincial and national leaders in colorectal cancer screening will assess the results of the strategy for use throughout Canada. Through the leadership of key stakeholders, this project brings a made-in-Alberta technology back to Alberta as a launching pad for the rest of Canada. For more information about PolypDx™ please visit: polypdx.com/.

The IHE is an independent, not-for-profit organization that performs excellence in health economics research and health technology assessment. Our core objectives include: supporting decision-making in health policy and practice with evidence from research in health economics and health technology assessment; assessing the medical, economic, social, and ethical implications of both established and new health practices, procedures, and technologies; and facilitating discussions and partnerships among government, academia, industry, and healthcare providers to address important issues in health care. Visit us at www.ihe.ca to learn more.

Contact:

Jasmine Brown
Director of Communications, Institute of Health Economics
Direct: (780) 401-1768 | Cell: (780) 966-4879
jbrown@ihe.ca

References:

  1. Canadian Cancer Statistics Advisory Committee. Canadian cancer statistics 2018. Toronto (ON): Canadian Cancer Society; 2018. Available from: www.cancer.ca/~/media/cancer.ca/CW/cancer information/cancer 101/Canadian cancer statistics/Canadian-Cancer-Statistics-2018-EN.pdf?la=en.

Downloads